ACELRX PHARMACEUTICALS INC Contracts & Agreements

Form of Amendment No. 1 to Securities Purchase Agreement, dated September 30, 2024, by and among Talphera, Inc. and entities affiliated with Nantahala Management, LLC (Filed With SEC on October 1, 2024)

Amended and Restated 2020 Equity Incentive Plan (Filed With SEC on June 24, 2024)

Amended and Restated 2011 Employee Stock Purchase Plan (Filed With SEC on June 24, 2024)

Payment Interest Purchase Agreement between the Registrant and XOMA (US) LLC, dated as of January 12, 2024 (Filed With SEC on May 14, 2024)

Form of Securities Purchase Agreement, dated January 17, 2024, by and among Talphera, Inc. and entities affiliated with Nantahala Management, LLC (Filed With SEC on January 22, 2024)

Form of Securities Purchase Agreement, dated January 17, 2024 by and among Talphera, Inc. and Investor Company ITF Rosalind Master Fund L.P (Filed With SEC on January 22, 2024)

Form of Registration Rights Agreement, dated January 17, 2024, by and among Talphera, Inc. and the Purchasers (Filed With SEC on January 22, 2024)

Form of Pre-Funded Warrant (January 2024) (Filed With SEC on January 22, 2024)

Asset Purchase Agreement, between the Registrant and Vertical Pharmaceuticals, LLC, dated March 12, 2023 (Filed With SEC on November 14, 2023)

Amended and Restated 2020 Equity Incentive Plan (Filed With SEC on October 10, 2023)

Form of Securities Purchase Agreement, dated July 17, 2023, by and between AcelRx Pharmaceuticals, Inc. and the Purchasers (Filed With SEC on July 21, 2023)

Form of Registration Rights Agreement, dated July 17, 2023, by and between AcelRx Pharmaceuticals, Inc. and the Purchasers (Filed With SEC on July 21, 2023)

Form of Series A common stock warrant (July 2023) (Filed With SEC on July 21, 2023)

Form of Series B common stock warrant (July 2023) (Filed With SEC on July 21, 2023)

Form of Pre-Funded Warrant (July 2023) (Filed With SEC on July 21, 2023)

Form of placement agent Series A common stock warrant (Filed With SEC on July 21, 2023)

Form of placement agent Series B common stock warrant (Filed With SEC on July 21, 2023)

Form of Common Warrant (December 2022) (Filed With SEC on December 29, 2022)

Form of Pre-Funded Warrant (December 2022) (Filed With SEC on December 29, 2022)

Form of Common Warrant, as amended (November 2021) (Filed With SEC on December 29, 2022)

Form of Securities Purchase Agreement, dated December 27, 2022 (Filed With SEC on December 29, 2022)

Common Stock Purchase Warrant, dated August 3, 2022 (Filed With SEC on August 4, 2022)

Securities Purchase Agreement, dated August 3, 2022, between AcelRx Pharmaceuticals, Inc. and Lincoln Park Capital Fund, LLC (Filed With SEC on August 4, 2022)

Registration Rights Agreement, dated August 3, 2022, between AcelRx Pharmaceuticals, Inc. and Lincoln Park Capital Fund, LLC (Filed With SEC on August 4, 2022)

Non-Employee Director Compensation Policy (Filed With SEC on March 10, 2022)

Second Amendment to Loan and Security Agreement between the Registrant and Oxford Finance, LLC, dated as of November 14, 2021 (Filed With SEC on March 10, 2022)

Contingent Value Rights Agreement, dated as of January7, 2022, by and among AcelRx Pharmaceuticals, Inc., James Wilkie, solely in his capacity as the representative of the Lowell... (Filed With SEC on January 12, 2022)

Agreement and Plan of Merger, dated as of November 14, 2021, by and among the Registrant, Lowell, Merger Sub 1, Merger Sub 2 and the Stockholder Representative (Filed With SEC on November 15, 2021)

License and Commercialization Agreement (DZUVEO), dated July 14, 2021, between Laboratoire Aguettant and the Registrant (Filed With SEC on November 15, 2021)

License and Commercialization Agreement (PFS), dated July 14, 2021, between Laboratoire Aguettant and the Registrant (Filed With SEC on November 15, 2021)

Form of CVR Agreement (Filed With SEC on November 15, 2021)

First Amendment to Loan and Security Agreement, dated as of May 5, 2021, between Oxford Finance, LLC and the Registrant (Filed With SEC on November 15, 2021)

Form of Warrant (Filed With SEC on November 15, 2021)

Purchase Agreement between the Company and the Purchasers, dated November 15, 2021 (Filed With SEC on November 15, 2021)

Commercial Supply Agreement, effective March 31, 2021 by and between Catalent Pharma Solutions, LLC and the Registrant (Filed With SEC on August 16, 2021)

Amended and Restated 2020 Equity Incentive Plan (Filed With SEC on June 17, 2021)

2021 Cash Bonus Plan Summary (Filed With SEC on May 17, 2021)

Non-Employee Director Compensation Policy (Filed With SEC on May 17, 2021)

Sublease for a Single Sublessee, dated March 26, 2021, by and between Weichert Workforce Mobility Inc., as successor in interest to The MI Group, Inc., and the Registrant (Filed With SEC on May 17, 2021)

Description of Capital Stock (Filed With SEC on March 15, 2021)

Non-Employee Director Compensation Policy (Filed With SEC on March 15, 2021)

2021 Cash Bonus Plan Summary (Filed With SEC on March 15, 2021)

Underwriting Agreement (Filed With SEC on January 21, 2021)

Distribution Agreement between the Registrant and Biomet 3i LLC d/b/a Zimmer Biomet Dental, dated July 17, 2020 (Filed With SEC on November 5, 2020)

Promotion Agreement among the Registrant, La Jolla Pharmaceutical Company and Tetraphase Pharmaceuticals, Inc., effective September 30, 2020 (Filed With SEC on November 5, 2020)

Non-Employee Director Compensation Policy (Filed With SEC on August 10, 2020)

Purchase Agreement between the Company and the Purchasers, dated July 22, 2020 (Filed With SEC on July 23, 2020)

Amendment No. 2 to Agreement and Plan of Merger, dated as of May 29, 2020, by and among the Registrant, Tetraphase and Merger Sub (Filed With SEC on May 29, 2020)

Form of Revised CVR Agreement (Filed With SEC on May 29, 2020)

Form of Amendment No. 2 to Voting Agreement (Filed With SEC on May 29, 2020)

Amendment No. 1 to Co-Promotion Agreement, dated as of May 26, 2020, by and between the Registrant and Tetraphase (Filed With SEC on May 29, 2020)

Amendment to Agreement and Plan of Merger, dated as of May 27, 2020, by and among the Registrant, Tetraphase and Merger Sub (Filed With SEC on May 27, 2020)

Form of Revised CVR Agreement (Filed With SEC on May 27, 2020)

Form of Amendment to Voting Agreement (Filed With SEC on May 27, 2020)

2020 Cash Bonus Plan Summary (Filed With SEC on May 11, 2020)

Transition Services Agreement and General Release (Filed With SEC on April 8, 2020)

Consulting Agreement (Filed With SEC on April 8, 2020)

Description of Capital Stock (Filed With SEC on March 16, 2020)

Non-Employee Director Compensation Policy (Filed With SEC on March 16, 2020)

2020 Cash Bonus Plan Summary (Filed With SEC on March 16, 2020)

Agreement between the Registrant and SpecGX, LLC, dated June 16, 2017 (Filed With SEC on November 7, 2019)

Amendment to Agreement between the Registrant and SpecGX, LLC, dated September 23, 2019 (Filed With SEC on November 7, 2019)

Non-Employee Director Compensation Policy (Filed With SEC on August 6, 2019)

Form of Warrant to Purchase Common Stock of the Registrant, dated as of May 30, 2019 (Filed With SEC on June 3, 2019)

Loan and Security Agreement with Oxford Finance LLC, dated as of May 30, 2019 (Filed With SEC on June 3, 2019)

2019 Cash Bonus Plan Summary (Filed With SEC on March 7, 2019)

Sublease by and between Registrant and Genomic Health, Inc. dated as of November 30, 2018 (Filed With SEC on March 7, 2019)

Underwriting Agreement, dated as of November 9, 2018, by and among AcelRx Pharmaceuticals, Inc., Credit Suisse Securities (USA) LLC and Jefferies LLC (Filed With SEC on November 13, 2018)

Underwriting Agreement, dated as of July 12, 2018, by and between AcelRx Pharmaceuticals, Inc. and Cantor Fitzgerald & Co (Filed With SEC on July 13, 2018)

Form of Performance-Based Stock Option Award under 2011 Equity Incentive Plan (Filed With SEC on May 10, 2018)

Offer Letter dated March 16, 2018 with John Saia (Filed With SEC on March 27, 2018)

Non-Employee Director Compensation Policy (Filed With SEC on March 9, 2018)

Amendment #2 to Manufacturing Services Agreement between the Registrant and Patheon Pharmaceuticals, Inc., effective as of August 4, 2017 (Filed With SEC on November 9, 2017)

SEPARATION AGREEMENT AND GENERAL RELEASE OF CLAIMS (Filed With SEC on August 2, 2017)

SECOND AMENDMENT TO LEASE (Filed With SEC on June 20, 2017)

QUANTITY (Filed With SEC on March 10, 2017)

amended and restated LOAN AND SECURITY AGREEMENT (Filed With SEC on March 3, 2017)

Summary of 2017 Cash Bonus Plan (Filed With SEC on February 9, 2017)

AcelRx Pharmaceuticals, Inc. Amended and Restated Severance Benefit Plan (Filed With SEC on February 9, 2017)

WARRANT MODIFICATION AGREEMENT (Filed With SEC on November 2, 2016)

2. Amendment to the COLLABORATION AND LICENSE AGREEMENT (Filed With SEC on November 2, 2016)

AMENDMENT NO. 3 TO AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT (Filed With SEC on November 2, 2016)

AcelRx Pharmaceuticals, Inc. Shares of Common Stock (par value $0.001 per share) Controlled Equity OfferingSM Sales Agreement (Filed With SEC on June 21, 2016)

Amendment #1 to Manufacturing Services Agreement Between Patheon Pharmaceuticals, Inc. and AcelRx Pharmaceuticals, Inc. (Filed With SEC on May 2, 2016)

Summary of 2016 Cash Bonus Plan (Filed With SEC on February 17, 2016)

AcelRx Pharmaceuticals, Inc. Severance Benefit Plan (Filed With SEC on February 17, 2016)

WARRANT MODIFICATION AGREEMENT (Filed With SEC on November 3, 2015)

First Amendment to the Collaboration and License Agreement (Filed With SEC on November 3, 2015)

First Amendment to the Manufacture and Supply Agreement dated December 16, 2013 (Filed With SEC on November 3, 2015)

PURCHASE AND SALE AGREEMENT between ACELRX PHARMACEUTICALS, INC., as Seller, and ARPI LLC, as Purchaser Dated as of September 18, 2015 TABLE OF CONTENTS (Filed With SEC on November 3, 2015)

SUBSEQUENT PURCHASE AND SALE AGREEMENT between ARPI LLC, as Seller, and PDL BIOPHARMA, INC., as Purchaser Dated as of September 18, 2015 TABLE OF CONTENTS (Filed With SEC on November 3, 2015)

CONSENT AND AMENDMENT NO. 2 TO AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT (Filed With SEC on November 3, 2015)

QUANTITY (Filed With SEC on August 4, 2015)

Summary of 2015 Cash Bonus Plan (Filed With SEC on May 5, 2015)

ACELRX PHARMACEUTICALS, INC. CONFIDENTIAL INFORMATION AND INVENTION ASSIGNMENT AGREEMENT (Filed With SEC on March 13, 2015)

EXHIBIT A SEPARATION DATE RELEASE (Filed With SEC on December 16, 2014)

AMENDMENT NO. 1 TO AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT (Filed With SEC on November 10, 2014)

/s/ Richard King (Filed With SEC on May 8, 2014)

SECOND AMENDMENT TO AMENDED AND RESTATED CAPITAL EXPENDITURE AND EQUIPMENT AGREEMENT (Filed With SEC on May 8, 2014)

FIRST AMENDMENT TO LEASE (Filed With SEC on May 7, 2014)

WARRANT AGREEMENT To Purchase Shares of the Common Stock of ACELRX PHARMACEUTICALS, INC. Datedas of December 16, 2013 (the Effective Date) (Filed With SEC on March 17, 2014)

AMENDED AND RESTATED LOAN ANDSECURITY AGREEMENT (Filed With SEC on March 17, 2014)

MANUFACTURE AND SUPPLY AGREEMENT (Filed With SEC on March 17, 2014)

COLLABORATION AND LICENSE AGREEMENT (Filed With SEC on March 17, 2014)

Summary of 2014 Cash Bonus Plan (Filed With SEC on February 10, 2014)

3,800,000 Shares1 ACELRX PHARMACEUTICALS, INC. Common Stock PURCHASE AGREEMENT (Filed With SEC on July 19, 2013)

Summary of 2013 Cash Bonus Plan (Filed With SEC on May 10, 2013)

Manufacturing Services Agreement for ARX-01 December 12, 2012 Table of Contents (Filed With SEC on May 8, 2013)

AMENDED AND RESTATED CAPITAL EXPENDITURE AND EQUIPMENTAGREEMENT (Filed With SEC on May 8, 2013)

[ ] Shares1 ACELRX PHARMACEUTICALS, INC. Common Stock PURCHASE AGREEMENT (Filed With SEC on December 5, 2012)

ACELRX PHARMACEUTICALS, INC. Common Stock (par value $0.001 per share) At Market Issuance Sales Agreement (Filed With SEC on August 31, 2012)

FORM OF WARRANT (Filed With SEC on May 30, 2012)

SECURITIES PURCHASE AGREEMENT (Filed With SEC on May 30, 2012)

LEASE BETWEEN METROPOLITAN LIFE INSURANCE COMPANY (LANDLORD) AND ACELRX PHARMACEUTICALS, INC. (TENANT) SEAPORT CENTRE Redwood City, California 1. TABLE OF CONTENTS (Filed With SEC on March 23, 2012)

QUARTERLY REPORT FORMAT (Filed With SEC on August 11, 2011)

WARRANT AGREEMENT To Purchase Shares of the Common Stock of ACELRX PHARMACEUTICALS, INC. Dated as of June 29, 2011 (the Effective Date) (Filed With SEC on June 30, 2011)

WARRANT AGREEMENT To Purchase Shares of the Common Stock of ACELRX PHARMACEUTICALS, INC. Dated as of June 29, 2011 (theEffective Date) (Filed With SEC on June 30, 2011)

LOAN AND SECURITY AGREEMENT (Filed With SEC on June 30, 2011)

Summary of 2011 Cash Bonus Plan (Filed With SEC on May 16, 2011)

ACELRX PHARMACEUTICALS, INC. NOTICE OF GRANT OF STOCK OPTION (Filed With SEC on March 30, 2011)

ACELRX PHARMACEUTICALS, INC. STOCK OPTION GRANT NOTICE (2011 EQUITY INCENTIVE PLAN) (Filed With SEC on March 30, 2011)

ACELRX PHARMACEUTICALS, INC. RESTRICTED STOCK UNIT GRANT NOTICE (2011 EQUITY INCENTIVE PLAN) (Filed With SEC on March 30, 2011)

ACELRX PHARMACEUTICALS, INC. NOTE AND WARRANT PURCHASE AGREEMENT (Filed With SEC on January 31, 2011)

[ ] Shares1 ACELRX PHARMACEUTICALS, INC. Common Stock PURCHASE AGREEMENT (Filed With SEC on January 7, 2011)

ACELRX PHARMACEUTICALS, INC. INDEMNIFICATION AGREEMENT (Filed With SEC on January 7, 2011)

ACELRX PHARMACEUTICALS, INC. 2011 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS:JANUARY 5, 2011 APPROVED BY THESTOCKHOLDERS: JANUARY [ ], 2011 TERMINATIONDATE: JANUARY... (Filed With SEC on January 7, 2011)

ACELRX PHARMACEUTICALS, INC. STOCK OPTION GRANT NOTICE (2011 EQUITY INCENTIVE PLAN) (Filed With SEC on January 7, 2011)

ACELRX PHARMACEUTICALS, INC. RESTRICTED STOCK UNIT GRANT NOTICE 2011 EQUITY INCENTIVE PLAN (Filed With SEC on January 7, 2011)

ACELRx PHARMACEUTICALS, INC. 2011 EMPLOYEE STOCK PURCHASE PLAN ADOPTED BY THE BOARD OF DIRECTORS:JANUARY 5, 2011 APPROVED BY THESTOCKHOLDERS: JANUARY [ ], 2021 (Filed With SEC on January 7, 2011)

FOUNDERS VESTING AGREEMENT (Filed With SEC on January 7, 2011)

ACELRX PHARMACEUTICALS, INC. EMPLOYMENT AGREEMENT (Filed With SEC on January 7, 2011)

EXHIBIT A CONFIDENTIAL INFORMATION AND INVENTION ASSIGNMENT AGREEMENT (Filed With SEC on January 7, 2011)

Category

Industry

Companies

Contracts

ACELRX PHARMACEUTICALS INC Contracts & Agreements